Tetratherix shares lift 30% on Superpower partnership on new precision medicine platform
Make us a preferred source
Make us a preferred source on Google
The news: Biotech Tetratherix has seen its shares surge in morning trade after announcing a new nasal delivery precision medicine franchise that includes an exclusive research and development agreement with health tech startup Superpower.
The numbers: At 12:17pm AEDT, shares in Tetratherix had lifted 30.1% to $5.41 and were up 63.9% in the year to date.
Under an exclusive research and development agreement Superpower will pay Tetratherix USD3 million ($4.28 million) licence payment per year for up to 10 years.
The context: Tetratherix’s precision medicine platform polymer STEPP can be used as a carrier for the nasal delivery of different compounds like peptides. It has been in “stealth” development for over five years, according to Tetratherix.
Tetratherix said the “precision medicine franchise is entirely additive and revenue generated” under the Superpower agreement will strengthen the company’s cash position as its core programs are funded to the start of FY28.
The company also reiterated that it remains on track to meet the milestones, outlined when it completed its IPO on 30 June 2025, across its bone regeneration, tissue spacing and tissue healing franchises.
What they said: “The establishment of the precision medicine franchise will unlock and accelerate additional opportunities and the execution of the Superpower agreement significantly expedites revenue from product commercialisation which is a great result for the business and its shareholders,” Tetratherix CEO Will Knox said.
The source: ASX
